Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Bexxar (Corixa Corp): Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Bexxar (Corixa Corp) - General Information

Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).

 

Pharmacology of Bexxar (Corixa Corp)

Bexxar binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin’s lympohomas. The antibody leads to selective killing of B-cells.

 

Bexxar (Corixa Corp) for patients

 

Bexxar (Corixa Corp) Interactions

No formal drug interaction studies have been performed. Due to the frequent occurrence of severe and prolonged thrombocytopenia, the potential benefits of medications that interfere with platelet function and/or anticoagulation should be weighed against the potential increased risk of bleeding and hemorrhage.

Drug/Laboratory Test Interactions

Administration of the BEXXAR therapeutic regimen may result in the development of human anti-murine antibodies (HAMA). The presence of HAMA may affect the accuracy of the results of in vitro and in vivo diagnostic tests and may affect the toxicity profile and efficacy of therapeutic agents that rely on murine antibody technology. Patients who are HAMA positive may be at increased risk for serious allergic reactions and other side effects if they undergo in vivo diagnostic testing or treatment with murine monoclonal antibodies.

 

Bexxar (Corixa Corp) Contraindications

The BEXXAR therapeutic regimen is contraindicated in patients with known hypersensitivity to murine proteins or any other component of the BEXXAR therapeutic regimen.

PREGNANCY CATEGORY X

Iodine I 131 Tositumomab (a component of the BEXXAR therapeutic regimen) is contraindicated for use in women who are pregnant. Iodine-131 may cause harm to the fetal thyroid gland when administered to pregnant women. Review of the literature has shown that transplacental passage of radioiodide may cause severe, and possibly irreversible, hypothyroidism in neonates. While there are no adequate and well-controlled studies of the BEXXAR therapeutic regimen in pregnant animals or humans, use of the BEXXAR therapeutic regimen in women of childbearing age should be deferred until the possibility of pregnancy has been ruled out. If the patient becomes pregnant while being treated with the BEXXAR therapeutic regimen, the patient should be apprised of the potential hazard to the fetus.

 

Additional information about Bexxar (Corixa Corp)

Bexxar (Corixa Corp) Indication: For treatment of non-Hodgkin's lymphoma (CD20 positive, follicular) Mechanism Of Action: Binds to the CD20 antigen which is found on mature B lymphocytes. The antibody binding appears to induce apoptosis, complement-dependent cytotoxicity and cell death through ionizing radiation. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Tositumomab Synonyms: Ig gamma-1 chain C region Drug Category: Antineoplastic Agents Drug Type: Biotech; Approved Other Brand Names containing Tositumomab: Bexxar (Corixa Corp); Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Most likely removed by opsonization via the reticuloendothelial system when bound to B lymphocytes, or by human antimurine antibody production Half Life: 0.8 hours (mammalian reticulocytes, in vitro) Dosage Forms of Bexxar (Corixa Corp): Kit Intravenous Chemical IUPAC Name: Murine anti-CD20 antibody Chemical Formula: C6416H9874N1688O1987S44 Tositumomab on Wikipedia: https://en.wikipedia.org/wiki/Tositumomab Organisms Affected: Humans and other mammals